Prothena Corporation Reports Q1 2025 Financial Results

Prothena Corporation ( (PRTA) ) has released its Q1 earnings. Here is a breakdown of the information Prothena Corporation presented to its investors.

Prothena Corporation is a late-stage clinical biotechnology company specializing in protein dysregulation, with a focus on developing treatments for neurodegenerative and rare peripheral amyloid diseases.

In its first quarter of 2025 financial results, Prothena reported a net loss of $60.2 million, an improvement from the previous year’s first quarter loss of $72.2 million. The company also highlighted several key developments in its clinical pipeline, including anticipated topline results from its Phase 3 AFFIRM-AL clinical trial for AL amyloidosis and multiple clinical readouts for its Alzheimer’s treatment, PRX012, expected throughout the year.

Key financial metrics for the first quarter include total revenue of $2.8 million, primarily from collaboration with Bristol Myers Squibb, and a decrease in research and development expenses to $50.8 million. Prothena’s cash position remains strong with $418.8 million in cash and no debt. The company continues to advance its pipeline with significant clinical milestones expected in 2025, including updates on its Alzheimer’s and Parkinson’s disease programs.

Looking forward, Prothena anticipates continued progress in its clinical trials and expects to end 2025 with approximately $301 million in cash. The company remains focused on advancing its investigational therapeutics towards commercialization, leveraging its expertise in protein dysregulation to address unmet medical needs.